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BACKGROUND: Oral squamous cell carcinoma (OSCC), the most common malignant 
neoplasm in oral cavity, is a significant worldwide public health threat. FXYD3 was 
reported to be overexpressed in prostate, breast, and pancreatic cancers, suggesting its 
role of carcinogenesis by providing a growth advantage, but downregulated in lung 
cancers comparing to the normal tissue. However, there have been no reports on the 
expression and role of FXYD3 in oral squamous cell carcinoma.  
METHODS: We generated two FXYD3-knockdown clones (SCC-4si and HO-1-U-1si) 
from the SCC-4 and HO-1-U-1 OSCC cell lines by transfection with small interfering 
RNA for FXYD3. Cell proliferation and in vitro migration assays were used to 
investigate the effect of FXYD3 downregulation on cell proliferation and migratory 
ability in SCC-4si and HO-1-U-1si. Immunohistochemistry was performed to evaluate 
the correlation between FXYD3 expression and proliferation in 60 OSCC tissue samples. 
RESULTS: The FXYD3-knockdown cells grew significantly slower than the control cells. 
SCC-4si cells proliferated at 35.7%, 60.9% and 62.7% of the rate of control cells at 24, 
48, and 72 hours after transfection, respectively (P<0.05). Also, HO-1-U-1si cells did at 
47.7%, 28.3% and 34.5%, respectively (P<0.05). FXYD3-knockdown cells showed 
reduced migratory ability. The migration percentages of SCC-4si cells were 37.2% and 
38.4% after 24 and 48h, respectively, compared with the control cells (P<0.05). Also, 
those of HO-1-U-1si cells were 33.3% and 44.1%, respectively (P<0.05). OSCC showed 
significantly higher FXYD3 expression than normal mucosa (P<0.05). The group with 
strong expression of FXYD3 had significantly higher Ki-67 labelling index than that with 
weak expression in OSCC tissue samples (P<0.05).  
CONCLUSION: These results suggest that the downregulation of FXYD3 induces anti-
proliferative and anti-migratory effects in OSCC and that FXYD3 might be a useful 
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I.     Introduction 
 
Oral squamous cell carcinoma (OSCC), the most common malignant neoplasm in oral 
cavity, is a significant worldwide public health threat [1]. The management of OSCC 
varies considerably, but standard procedure includes surgery with or without neck 
dissection, followed by adjuvant radiotherapy [2]. Despite all efforts and therapeutic 
developments, the 5-year survival rate for head and neck cancers has not remarkably 
improved over the last two decades [1, 3]. In addition, a high percentage of patients have 
a poor response to therapy and high recurrence rates 〔4〕. Therefore, there has been much 
interest in the development of novel molecular targets for treatment of OSCC.  
The FXYD protein family is a small membrane proteins that have a molecular mass 
between 7.5 and 24kDa, and all members of the family share a signature sequence of six 
highly conserved amino acids comprising the FXYD motif (Phe-Xaa-Tyr-Asp) in the 
NH2-terminus, and two glycines and one serin residue in the transmembrane domain 〔5〕.  
Mammary tumor 8 kDa (MAT8)/FXYD domain-containing ion transport regulator 3 
(FXYD3) was first identified in murine breast cancer induced by the neu and ras 
oncogenes, and involved in the regulation of chloride conductance 〔6〕. Recent studies 
showed that FXYD3 was overexpressed in several types of malignant tumors such as 
prostate, breast, pancreatic cancers, suggesting that it induces carcinogenesis by providing 
a growth advantage [7, 8, 9]. Contrary to the reports, FXYD3 seems to be downregulated 
in lung cancer comparing to the normal tissue 〔10〕. Thus, FXYD3 could play diverse 
roles in different instances and its significance in carcinogenesis could vary in type of 
cancer.  
However, to our knowledge, there have been no reports on the expression and 
biological role of FXYD3 in oral squamous cell carcinoma. Therefore, in the present 
study, we investigated the expression of FXYD3 in OSCC cell lines and tissue samples, 
effects on cell proliferation and migration of FXYD3-downregulated OSCC cells, and 
the correlation between FXYD3 expression and proliferation in OSCC tissue samples.  
II.      Materials and Methods 
 
Cell cultures 
SCC-4, SCC-9, SCC-15, SCC-25, HSC-2, HSC-3, HSC-4, and HO-1-U-1 human OSCC 
cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 
antibiotics (100 U/ml penicillin and 100 g/ml streptomycin). SCC-4, SCC-9, SCC-15, and 
SCC-25 were purchased from American Tissue Cell Collection (Manassas, VA, USA). 
HSC-2, HSC-3, HSC-4, and HO-1-U-1 cells were kindly gifted from Prof. Takata 
(Hiroshima University, Hiroshima, Japan).  
 
siRNA transfection 
A siRNA for FXYD3 (siFXYD3; 5’-CGCCAATGACCTAGAAGATAA-3’) and non-
silencing control (NSC; 5’-AATTCTCCGAACGTGTCACGT-3’) were purchased from 
Qiagen (Hilden, Germany). SCC-4 and HO-1-U-1 OSCC cells were transfected using the 
Hiperfect transfection reagent (Qiagen) following the manufacturer’s instructions. Briefly, 
1 x 10
6
 cells were seeded in 6-well plate (SPL, Seoul, Korea) in complete cell culture 
medium. After overnight incubation, the cells were transfected with siFXYD3 or NSC at 
a concentration of 50nM, using Hiperfect transfection reagent (6 ㎕/ml). Transfected 
cells were named to SCC-4si and HO-1-U-1si, respectively. 
RNA preparation and semi-quantitative RT-PCR 
The mRNA was purified from the cells using Trizol reagent (Invitrogen, CA, USA) 
according to the manufacturer’s recommended protocol. Two micrograms of RNA was 
converted into cDNA using random primers and reverse transcriptase (GeneDePot, CA, 
USA). cDNA was PCR amplified in 30 cycles each consisting of 94℃ for 30 s, 60℃ for 
50 s, 72℃ for 50 s.  
The primer pairs for FXYD3 and GAPDH were as follows ; FXYD3 forward, 5’- CCG 
GTC GCG AGA CTG TAC GTC TT–3’ ; FXYD3 reverse, 5’–CTG GGG ACA GAG 
AAC GGT CCT CC-3’; GAPDH forward, 5’- GAA GGT GAA GGT CGG AGT C-3’; 
GAPDH reverse, 5’- CAA AGT TGT CAT GGA TGA CC -3’. PCR products were 




Briefly, 70-80% confluent cells were homogenized with 1 ml of lysis buffer (10 mM 
HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF) and 
incubated on ice. To the homogenates was added 125 μl of 10% NP-40 solution, and the 
mixture was then centrifuged for 30 sec at 12,000×g. Supernatant protein was normalized. 
Fifty micrograms of protein was size-fractionated through a 15% SDS-PAGE gel, 
transferred to PDVF membrane, and immunoblotted with the anti-FXYD3 (A-8; Santa 
Cruz, USA) and anti-α tubulin (B-5-1-2; Santa Cruz) mouse monoclonal antibodies.  
 
Cell proliferation assay 
To determine the proliferation rate, cells were seeded on 12-well plates (BD Falcon, 
Franklin Lakes, NJ, USA) at 3 x 10
4 
cells per well in serum-free media. After overnight of 
incubation, the cells were transfected with siFXYD3 or NSC. And then, after 24, 48, and 
72 h, the cells were trypsinized and stained with 0.4% Trypan Blue (Gibco, USA). The 
total cell number and the proportion of dead cells were counted by hemocytometer. Cell 
death was determined by the presence of cytoplasmic staining. This assay was performed 
in triplicate in each experiment, and each experiment was repeated three times. 
 
In vitro migration assay 
10
5
 cells were placed in the upper compartment (8 μm pore size) of a cell culture insert 
(BD Falcon). After overnight incubation, cells were transfected with siFXYD3 or NSC. 
Conditioned medium was added to the lower compartment. Then, after 24 and 48h, the 
cells on the upper surface of the filter were wiped off with a cotton swab, and the 
remaining cells were stained with the Diff-Quick stain set (Sysmex, Kobe, Japan). Using 
a microscope at x 100 magnification, migration was quantified by counting the number 
of cells that migrated through the pores to the lower side of the filter. This assay was 
performed in triplicate in each experiment, and each experiment was repeated 3 times. 
Tissue samples and immunohistochemistry 
Tissue samples of 60 OSCCs were retrieved from the Oral Pathology Registry of Seoul 
National University Dental Hospital from 2002 to 2006. Tissues were fixed in 10% 
buffered-formalin and embedded in paraffin. Immunohistochemistry was performed on 4 
m paraffin sections mounted on silicon-coated glass slides, using streptavidin-biotin 
peroxidase technique as previous described [11, 12]. An anti-human FXYD3 mouse 
monoclonal antibody (C-20; diluted 1:200, Santa Cruz) and anti-human Ki-67 mouse 
monoclonal antibody (MIB-1; diluted 1:100, Dako) were used. Staining at the cytoplasm 
or cell membrane was considered as FXYD-3 positive. The intensity of the staining was 
graded as negative (no positive cells), weak (< 20% positive cells), moderate (20–50% 
positive cells) and strong positive (>50% positive cells). In statistical analysis, we 
considered negative, weak and moderate staining as weak group, and strong staining as 
strong group [13]. Available 17 cases of normal mucosa within the tissue samples were 
evaluated. For Ki-67, nuclei from over 1000 tumor cells were counted in the five to eight 
random fields chosen for each sample and the count was expressed as the percentage of 
Ki-67 positive cells (Ki-67 labelling index; LI). All procedures followed in this study 
were in accordance with the guidelines of the Institutional Review Board of the Seoul 
National University Dental Hospital.  
 
Statistical analysis 
Statistical significance was assessed by comparing mean (SD) values with Student’s t-
test for independent groups or 
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FXYD3 expression and screening of OSCC Cell Lines 
Of 8 OSCC cell lines, all of those except HSC-4 showed clear expression of FXYD3 
mRNA in RT-PCR analysis. And in Western blot, the prominent expression of FXYD3 
protein was detected in SCC-4, SCC-15, HSC-4 and HO-1-U-1 (Fig. 1). Considering the 
above results, SCC-4 and HO-1-U-1 cell lines were chosen for this study.  
 
Confirmation of FXYD3 knockdown by siRNA 
SCC-4 and HO-1-U-1 cells were transfected with siFXYD3 or NSC. Therefore, we 
assayed for siRNA-mediated FXYD3 knockdown by RT-PCR analysis, and we found 
FXYD3 downregulation in SCC-4si and HO-1-U-1si cells (Fig. 2A). By western blot 
analysis, FXYD3 was also downregulated in SCC-4si and HO-1-U-1si cells until 72h 
after transfection (Fig. 3B). Therefore, FXYD3 was knocked down at both the mRNA 
and protein levels in SCC-4si and HO-1-U-1si cells 
 
Anti-proliferative effects of FXYD3 down-regulation 
From the cell proliferation assay, we found that the FXYD3-knockdown cells grew 
significantly slower than the NSC-transfected control cells (Fig. 3). SCC-4si cells 
proliferated at 35.7%, 60.9% and 62.7% of the rate of control cells at 24, 48, and 72 hours 
after transfection, respectively (P<0.05). Also, HO-1-U-1si cells did at 47.7%, 28.3% and 
34.5%, respectively (P<0.05). These data indicated that the down-regulation of FXYD3 
has an anti-proliferative effect on OSCC cells.  
 
Reduced migratory ability by FXYD3 down-regulation 
FXYD3-knockdown cells showed reduced migratory ability (Fig. 4). The migration 
percentages of SCC-4si cells were 37.2% and 38.4% after 24 and 48h, respectively, 
compared with the NSC-transfected control cells (P<0.05). Also, those of HO-1-U-1si 
cells were 33.3% and 44.1%, respectively (P<0.05). These data indicate that 
downregulation of FXYD3 has an anti-migratory effect. 
 
FXYD3 expression and Ki-67 LI in OSCC Tissues 
We examined FXYD3 expression and Ki-67 LI in the biopsy specimens from 60 patients 
with OSCC. FXYD3 protein was detected in the cytoplasm and/or the cell membrane and 
Ki-67 was detected in the nucleus by immunohistochemistry (Fig. 5). Of 60 OSCC cases, 
twenty-seven (45.0%) expressed FXYD3 strongly, 14 (23.3%) moderately, fifteen (25.0%) 
faintly, and 4 (6.7%) not at all. Of 17 normal mucosa cases, eleven (64.7%) expressed 
FXYD3 faintly, and 6 (35.3%) negatively. OSCC showed significantly higher FXYD3 
expression than normal mucosa (P<0.05). Ki-67 LI was 54.43  15.83 in FXYD3-strong 
group and 35.36  14.67 in FXYD3-weak group. There was significant correlation 





In the present study, we induced FXYD3 downregulation by siRNA in SCC-4 and HO-1-
U-1 OSCC cells and generated FXYD3 knockdown cells, SCC-4si and HO-1-U-1si. We 
then investigated the effect of FXYD3 downregulation on cell proliferation and migration. 
Downregulation of FXYD3 induced anti-proliferative and anti-migratory effects in these 
OSCC cells. To our knowledge, this is the first description of siRNA-mediated FXYD3 
knockdown in oral cancer cells.  
The FXYD proteins constitute a family of conserved auxiliary subunits of the Na, K-
ATPase and have been the study focus in biomedicine field recently due to their ability to 
finely regulated the activity of the enzyme complex in various physiological and 
pathological settings 〔14〕. In mammals, the FXYD family contains seven members 
including phospholemman (FXYD1) 〔15〕, the Na,K-ATPase γ-subunits (FXYD2) 〔16〕, 
mammary tumor marker 8 (Mat-8) (FXYD3) 〔6〕, corticosteroid hormone-induced factor, 
CHIF (FXYD4) 〔17〕,  protein related to ion channel, Ric (FXYD5) 〔18〕, 
phophohippolin (FXYD6) 〔19〕, and FXYD7 〔20〕. These family members have a 
molecular mass between 7.5 and 24kDa. They share a common signature of 6 amino acid 
residues, comprising the FXYD motif, from which the family takes its name, 2 glycine 
residues and a serine residue. Among them, FXYD3 is able to associate with and modify 
the transport proteins of Na-K-ATPase, and to interact with Na-K-ATPase as a chloride 
channel or a chloride channel regulator. 
Studies on the expression of FXYD3 in cancer have mainly been shown that its 
overexpression was detected during carcinogenesis. In addition to the studies in breast, 
prostate, and pancreatic cancers [6, 7, 8], Zhang et al. [21] reported that FXYD3 protein 
is highly expressed in majority of urothelial carcinoma of the upper genitourinary tract 
and bladder compared to normal kidney and bladder tissues. It was known that FXYD3 
was highly expressed in colorectal cancers compared to adjacent normal mucosa [22]. 
Also, Zhu et al. [23] presented that overexpression of FXYD-3 is involved in the 
tumorigenesis and development of esophageal cancers. In agreement with these, our study 
showed FXYD3 was highly expressed in OSCC compared to adjacent normal mucosa. In 
contrast to our results, Okudela et al. [10] reported that FXYD3 mRNA and protein levels 
were lower in most of the lung cancer cell lines than in either the noncancerous lung 
tissue or airway epithelial cell and protein levels were also lower in a considerable 
proportion of primary lung cancers than in nontumoral airway epithelia. This 
inconsistency could result from diverse roles of FXYD3 according to type of cancer.  
siRNA-mediated downregulation of FXYD3 expression in human prostate cancer cells 
leads to a significant decrease in cellular proliferation [7]. Also, Yamamoto et al. [24] 
reported that cell proliferation rate of MCF-7 breast cancer cells was drastically decreased 
when FXYD3a and 3b mRNAs were suppressed by the small interfering RNA. In 
agreement with previous studies, the FXYD3-knockdown cells derived from SCC-4 and 
HO-1-U-1 OSCC cell line grew significantly slower than control cells in the current study. 
These data indicate that the FXYD could play an important role in the proliferation of 
oral cancer cells and FXYD3 downregulation might be an effective anti-cancer strategy in 
oral cancer. 
In order to support our results on anti-proliferative effects of FXYD3 downregulation in 
vitro, we investigated the correlation between FXYD3 expression and proliferation in 
OSCC tissue samples. In the present study, FXYD3-strong group had significantly higher 
Ki-67 LI than FXYD3-weak group. These findings are consistent with our in vitro results, 
which the FXYD3-knockdown cells grew significantly slower than the control cells. 
Additional work is under way to determine signaling pathways and molecules responsible 
for the effect of FXYD3 downregulation on cell proliferation in OSCC cells. 
In summary, we obtained two FXYD3-knockdown clones (SCC-4si and HO-1-U-1si) 
from the SCC-4 and HO-1-U-1 OSCC cell lines, in order to investigate the effect of 
FXYD3 downregulation on cell proliferation and migration. The FXYD3-knockdown 
cells grew significantly slower than the control cells. SCC-4si cells proliferated at 35.7%, 
60.9% and 62.7% of the rate of control cells at 24, 48, and 72 hours after transfection, 
respectively. Also, HO-1-U-1si cells did at 47.7%, 28.3% and 34.5%, respectively. 
FXYD3-knockdown cells showed reduced migratory ability. The migration percentages 
of SCC-4si cells were 37.2% and 38.4% after 24 and 48h, respectively, compared with 
the control cells. Also, those of HO-1-U-1si cells were 33.3% and 44.1%, respectively. 
OSCC showed significantly higher FXYD3 expression than normal mucosa. The group 
with strong expression of FXYD3 had significantly higher Ki-67 labelling index than that 
with weak expression in OSCC tissue samples. These data suggest that the 
downregulation of FXYD3 induces anti-proliferative and anti-invasive effects in OSCC 
and that FXYD3 might be a useful target molecule for the treatment of OSCC. 
  
V.      Conclusion 
These results suggest that the downregulation of FXYD3 induces anti-
proliferative and anti-migratory effects in OSCC and that FXYD3 might be a 
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Fig. 1. Screening of OSCC cell line for FXYD3 expression by RT-PCR (upper and 
middle panals) and Western blot (lower panel). SCC-4 and HO-1-U-1 showed prominent 
FXYD3 expression. 
 
Fig. 2. Confirmation of FXYD3 Knockdown by siRNA. RT-PCR (A) and Western blot 
(B) analysis showed that FXYD3 mRNA and protein were efficiently downregulated in 
SCC-4si and HO-1-U-1si. 
 
Fig. 3. Anti-proliferative effects of FXYD3 downregulation. Cell proliferation assay 
showed that the FXYD3-knockdown cells grew significantly slower than the NSC-
transfected control cells. SCC-4si cells proliferated at 64%, 39% and 37% of the rate of 
control cells at 24, 48, and 72 hours after transfection, respectively (P<0.05). Also, HO-1-
U-1si cells did at 59%, 74% and 69%, respectively (P<0.05). 
 
Fig. 4. Reduced migratory ability by FXYD3 downregulation. FXYD3-knockdown cells 
showed reduced migratory ability. The migration percentages of SCC-4si cells were 37.2% 
and 38.4% after 24 and 48h, respectively, compared with the NSC-transfected control 
cells (P<0.05). Also, those of HO-1-U-1si cells were 33.3% and 44.1%, respectively 
(P<0.05). 
 
Fig. 5. Representative immunohistochemical analysis of FXYD3 and Ki-67 in OSCC, 
showing both (A) positive expression of FXYD3 and (B) high level of Ki-67 expression 

















































































































FXYD3발현 저하 유도가 구강편평세포암종에서 세포 
증식과 이동 능력 억제 효과에 관한 연구 
조 병 찬 
서울대학교대학원 치의학과 구강병리과 전공 
(지도교수: 홍 삼 표) 
구강 편평세포암종은 두경부암 중에서 가장 흔한 형태의 암종으로, 인류의 
건강에 커다란 위협이 되고 있다. 최근 연구에 따르면, FXYD3 는 유방암, 
전립선암, 그리고 췌장암에서 과발현되며, 따라서 종양형성에서 성장을 
촉진하는데 역할을 한다고 보고되고 있다. 반면에 폐암에서는 FXYD3 의 
발현이 정상조직과 비교하였을 때, 감소되었다고 보고된 바 있다. 이러한 
보고들의 불일치를 미루어 보았을때, FXYD3 는 발암유전자 또는 종양 억제 
유전자 역할 둘 다 할 수 있다는 것을 짐작할 수 있다. 하지만, 구강 편평 
세포 암종의 종양형성 과정에서 FXYD3 가 어떠한 역할을 하는지는 현재 
보고된 바가 없다. 따라서, 본 연구에서 구강 편평세포암종 세포에서 
FXYD3 의 발현 정도를 확인하고, FXYD3 의 발현 저하가 종양 형성에 
관여하는 세포 증식능과 이주능에 어떠한 역할을 하는지 알아보고자 하였다. 
구강 편평세포암종 세포주 SCC-4 와 HO-1-U-1 에 FXYD3 siRNA 를 
형질주입시켜 FXYD3 가 발현저하된 세포들을 (SCC-4si 와 HO-1-U-1si) 
획득하였다. 이 세포들에서 FXYD3 발현저하가 세포 증식능과 이주능에 
미치는 영향을 확인하고자 cell proliferation assay 와 in vitro migration 
assay 를 시행하였다. 또한, 60명의 구강 편평세포암종 환자의 조직 시편에서 
FXYD3 발현과 증식 정도를 평가하기 위하여 면역조직화학적 분석을 하였다.  
FXYD3 가 발현저하된 세포들은 대조군에 비해 증식능이 감소하였다. SCC-
4si 세포들의 형질주입 24, 48, 72 시간 후의 세포 증식은 각각 대조군의 
35.7%, 60.9%, 62.7%의 비율을 보였다 (P<0.05). HO-1-U-1si 들의 경우는 
각각 47.7%, 28.3%, 34.5%를 나타냈다 (P<0.05). 또한, FXYD3 가 
발현저하된 세포들은 감소된 이주능을 보였다. SCC-4si 세포들의 형질주입 
24, 48 시간 후의 세포 이동 비율은 각각 대조군의 37.2%, 38.4%였다 
(P<0.05). HO-1-U-1si 들의 경우는 각각 33.3%, 44.1%를 나타냈다 
(P<0.05). 구강 편평세포암종 환자의 조직 시편에서 FXYD3 발현이 인접 정상 
점막 조직에 비해 유의성 있게 높았다 (P<0.05). 구강 편평세포암종에서 
FXYD3 고발현 군의 Ki-67 지수가 저발현 군에 비해 유의성 있게 높았다 
(P<0.05). 이러한 결과들로 보아, FXYD3 의 발현저하는 구강 편평세포암종 
세포의 증식능과 이주능에 대한 억제 효과를 나타내며, 구강 편평세포암종 
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